ACSL4 deficiency confers protection against ferroptosis-mediated acute kidney injury

• Published in: Redox biology Vol. 51; p. 102262
• Main Authors: Wang, Yue, Zhang, Menghan, Bi, Ran, Su, Yali, Quan, Fei, Lin, Yanting, Yue, Chongxiu, Cui, Xinmeng, Zhao, Qixiang, Liu, Siliang, Yang, Yong, Zhang, Dayong, Cao, Qiuhua, Gao, Xinghua
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2022; Elsevier
• Subjects: ACSL4; Acute kidney injury; Acute Kidney Injury - metabolism; Animals; Coenzyme A Ligases - genetics; Female; Ferroptosis; Ferroptosis - genetics; HIF-1α; Humans; Macrophages; Male; Mice; Research Paper; Rosiglitazone - pharmacology; Ferroptosis; ACSL4; HIF-1α; Macrophages; Acute kidney injury
• ISSN: 2213-2317; 2213-2317
• DOI: 10.1016/j.redox.2022.102262

The term ferroptosis coined in 2012 causes acute kidney injury (AKI). However, its pathway mechanism in AKI is poorly understood. In this study, we conducted an RNA-sequence analysis of kidneys in AKI and normal mice to explore the pathway mechanism of ferroptosis. Consequently, differentially expressed genes highlighted Acyl-CoA synthetase long-chain family (ACSL4), a known promotor for ferroptosis. Besides, RT-PCR, Western blot, and immunohistochemical analyses confirmed its upregulation. HIF-1α was downregulated in I/R-AKI mice, and in vitro studies confirmed a negative regulation of HIF-1α on ACSL4. To explore the role of ACSL4 in AKI, we constructed ACSL4 knockout in kidney tubules of mice-as Cdh16Cre-ACSL4F/F mice. Results revealed that ACSL4 knockout significantly reduced ferroptosis and inhibited the functional and pathological injury of AKI mice. Meanwhile, the kidneys of Cdh16Cre-ACSL4F/F mice demonstrated a significantly decreased inflammation and macrophage infiltration. Further, additional explorations were explored to decipher a more thorough understanding of ferroptotic immunogenicity. As a result, neutrophils were not directly recruited by ferroptotic cells, but by ferroptotic cell-induced macrophages. Further, ACSL4 inhibitor rosiglitazone significantly inhibited AKI. Collectively, these data provide novel insights into the AKI pathogenesis, and defined ACSL4 as an effective target in AKI. Proposed effects of ACSL4 in AKI. Low HIF-1α induces a high expression of ACSL4 and leads to the ferroptosis and inflammation during the occurrence of AKI. Ferroptotic cells recruit macrophages, then induce the neutrophils recruitment to the kidney injury site, producing several inflammatory cytokines and inducing an inflammatory cascade. Therefore, ACSL4 could be a potential target for the prevention and treatment of AKI. [Display omitted]